Oslo University Hospital - One of the Three Members of the Norwegian Cancer Consortium
Each issue of GAP Connect from now until the annual GAP Conference 2012 in Oslo, Norway from May 14-16 will feature news and updates about the conference and the Norwegian Cancer Consortium. The NCC is comprised of Stavanger University Hospital, Oslo University Hospital (OUH) and the Cancer Registry of Norway. When MD Anderson signed their initial Sister Institution agreement with NCC, Radium Hospital represented the Norwegian consortium of entities. But in 2009, Oslo University Hospital was created by the merger of three hospitals: Rikshospitalet - Radiumhospitalet, Ullevål University Hospital and Aker University Hospital . That merger created one of the largest hospitals in Northern Europe.
In July 2011, the Division of Cancer Surgery merged with the Division of Surgery and Transplantation. Now known as the Division of Cancer Medicine, Surgery and Transplantation, more than 3000 employees support the cancer care, research and education efforts of the division. The division produces around 500 scientific publications and 35 PhDs a year and accounts for approximately 40% of the total research at the hospital. As part of the medical faculty at the University of Oslo, Norway's largest university, the division is able to provide additional cooperative research opportunities. Both Radium Hospital and the Institute for Cancer Research are now part of this division.
As a unique entity within the division, the Institute for Cancer Research is comprised of three centers: Center for Cancer Biomedicine, which is a center of excellence; Cancer Stem Cell Innovation Center, which is a center for research-driven innovation; and the K.G. Jebsen Center for Excellence in Breast Cancer Research. The Center for Cancer Biomedicine provides a multidisciplinary approach to integrating cancer related biological information across disciplines. The teams include cell biologists, translational cancer scientists and computational biologists - all working to define the biologic systems of cancer and improve the life of the patient. While the Center for Cancer Biomedicine was created to help researchers collaborate, innovation centers like the Cancer Stem Cell Innovation Center are intended to help focused research groups and industry interact. Finally the K.G. Jebsen Centre for Breast Cancer Research is working towards developing personalized therapy for breast cancer.
In addition to the three centers, seven research departments within the institute house groups in biochemistry, cell and tumor biology, genetics radiation biology, immunology and cancer prevention. These departments work cooperatively with cancer surgeons, oncologists and pathologists to produce translational results on behalf of OUH. Approximately 70% of employees and projects within the institute are externally funded. In 2009 the institute took up residence in a new building equipped with animal facilities, bioinforamtics, confocal microscopy, electron microscopy, flow cytometry, preteomics, microarray and sequencing and genotyping. A magenetic resonence facility for animals is scheduled to open in 2012.
Calendar of Events
|CMSI Annual Symposium|
Feb. 27, 2012
MD Anderson Espana Conference
GAP Annual Conference
GAP Connect Will Now Be Bi-Monthly
Starting this month, GAP Connect will begin to be delivered on the first and third Tuesday of each month. We continue to seek input on your work and content and information you would like to see in GAP Connect. Please contact us with story ideas, conferences at your institution and special events. Keep reading GAP Connect for all the latest in what is happening with in our Sister Institution Network and other projects and relationships.
Final Program for MD Anderson España Joint Conference
From March 14-16, 2012, physicians at The University of Texas MD Anderson Cancer Center and MD Anderson Cancer Center - España will gather in Madrid to hold the III MD Anderson International Conference in Gynecologic Oncology. Entitled Designing the Future, the conference will be directed by MD Anderson - España physicians Luis Chiva, M.D., chief of the Department of Gynecologic Oncology and Antonio González Martin, M.D., chief of the Department of Medical Oncology, as well as MD Anderson's Pedro Ramirez, M.D., professor in the Department of Gynecologic Oncology & Reproductive Medicine. The conference will cover topics including the molecular biology of gynecologic cancer, principles of translational research, integrating targeted therapy into clinical practice, minimally invasive and conservative surgery, and controversies in the field. David Gershenson, M.D., chairman of MD Anderson's Department of Gynecologic Oncology will provide the keynote lecture for the event. Read the program for all the details.
If you plan on attending the conference and have any questions, please contact Laura Flores. Read more about hotels and directions to the event and register by filling out the form and faxing or emailing to Ms. Flores. The english version is on the second page. Advanced registration ends on March 7, 2012. You can also find all of this information on MD Anderson España's website.
WIN, Worldwide Innovative Networking in personalized cancer medicine was started jointly by MD Anderson Cancer Center and Institut Gustave Roussy in France. The coalition of 22 cancer centers and industry partners are working to increase the efficacy of cancer diagnostics and therapeutics. This year marks the fourth annual symposium for the group and will be held in Paris, France from June 28-29, 2012. The theme of this year’s symposium is the Efficacy of Biomarkers and Personalized Cancer Therapeutics. Read the website's program for more specifics on the speakers, who include MD Anderson current president, Ronald DePinho, M.D., Ph.D. and past president John Mendelsohn, M.D. Follow the links below to register or submit an abstract. The deadline for abstract submissions is May 1, 2012. Early registration ends on April 1, 2012. Visit the WIN website for more information and background on the symposium.
Barretos Cancer Hospital Continues to Strengthen Its Prevention Programs
The January 24th issue of GAP Connect reported on Barretos Cancer Hospital's choice of Ji-Paraná, a city in the state of Rondônia, Brazil, as the site of a new Institute of Cancer Prevention. Now, in Fernandópolis, a remote city nearly 350 miles from the capital of São Paulo in the state of the same name, the foundation that supports Barretos Cancer Hospital is investing in an additional location for cancer prevention. The foundation will be incorporating and existing hospital facility to create the Advanced Unit of Cancer Prevention Fernandópolis. Between the new facility, the main cancer hospital in Barretos and an additional location in Jales, the combined units expect to cover 50% of the population in the state of São Paulo with mammography for women between 40 and 69 within two years and Pap tests within three years.
Recent videos from MD Anderson's Global Academic Programs.
|Ronald DePinho, M.D., discusses his plans for MD Anderson shortly after taking over as president.|
|Raymond DuBois, M.D., Ph.D., provost of MD Anderson discusses chronic inflammation in colorectal cancer.|
|Past President of MD Anderson discusses 2011 WIN Symposium|
Read More About GAP in MD Anderson's Cancerwise blog
Keep up with the latest in cancer treatment, research, education and prevention.